Drug Pricing on Capitol Hill: Three Threads Driving the Debate This Week

Key Takeaways

1. Trump wants Congress to lock in his drug pricing deals — but his own party isn't sold. The president used his State of the Union address to push lawmakers to codify Most Favored Nation pricing into law. Congressional Republicans are balking, citing free-market concerns and a lack of legislative detail.

2. PBM reform is now law — and members are taking victory laps. The recently enacted Consolidated Appropriations Act included landmark pharmacy benefit manager reforms requiring 100 percent rebate pass-through. Sen. Marsha Blackburn and other Republicans are framing it as a signature achievement on medication affordability.

3. Drug supply chain security is emerging as a bipartisan priority. Multiple members are linking domestic pharmaceutical manufacturing to national security, laying groundwork for potential legislation that intersects with prescription drug costs and trade policy.

Most Favored Nation Drug Pricing: The White House Wants a Law, Congress Isn't Ready

The dominant storyline in drug pricing legislation this week centers on a collision between the White House and Capitol Hill Republicans over whether to make President Trump's Most Favored Nation pricing framework permanent.

During his State of the Union address on February 24, Trump urged Congress to act, claiming: "I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest." The MFN framework, which Trump has implemented through executive action and the TrumpRx platform, pegs what the U.S. government pays for certain drugs to the lowest prices paid by other developed nations — a form of international reference pricing that has long been discussed in Medicare drug price negotiation debates.

But Politico reported that GOP lawmakers are showing reluctance to turn these deals into statute. The obstacles are both ideological and practical: longstanding Republican free-market orthodoxy clashes with what amounts to government-set pricing, and the administration has not provided Congress with detailed legislative text to work from. The Politico Pulse newsletter characterized the situation as "Trump's drug-pricing hurdle," signaling this will be a drawn-out negotiation rather than a quick legislative win.

Adding complexity, Axios reported that the vast majority of Americans — particularly those with private insurance — may not actually feel the impact of Trump's drug price reductions. The MFN deals and TrumpRx platform primarily offer direct-to-consumer cash prices that don't count toward insurance deductibles, limiting their practical reach for the privately insured population.

Meanwhile, advocacy group Protect Our Care released a memo arguing that the administration has done little to meaningfully address prescription drug costs, calling the MFN executive order "a wishlist for Big Pharma." The group highlighted that the administration exempted top-selling drugs like Keytruda and Opdivo from Medicare drug price negotiation and is seeking to delay negotiations for small molecule drugs.

No specific legislation to codify MFN has been introduced this week, and no hearings on the topic are currently scheduled. The lack of legislative vehicle is itself a telling indicator of the challenge ahead.

The pharmaceutical industry remains heavily engaged on this front. Brand-name manufacturers including Merck, Eli Lilly, Bristol Myers Squibb, and AstraZeneca co-founded the IRA Watchdog lobbying group specifically to influence drug pricing policy implementation. PhRMA, the industry's lead trade association, has filed lawsuits challenging Medicare negotiation provisions and remains the most prominent industry voice opposing government-set pricing mechanisms. On the other side, Patients For Affordable Drugs and AARP continue to advocate for stronger federal action on medication affordability.

The tension here is unusual: a Republican president pushing a pricing policy that many in his own party view as government overreach, while Democrats who have long championed Medicare drug price negotiation watch from the sidelines. How this resolves will shape the drug pricing landscape for years.

Pharmacy Benefit Manager Reform: A Landmark Law Takes Effect

The second major thread this week is the aftermath of Congress passing significant pharmacy benefit manager reforms as part of the 2026 Consolidated Appropriations Act. According to legal analysis from Mintz, the law requires PBMs to pass through 100 percent of rebates to plan clients and imposes new transparency and reporting requirements — one of the most consequential changes to how prescription drug costs flow through the supply chain in recent memory.

Members of Congress are wasting no time claiming credit. Sen. Marsha Blackburn (R-TN) posted on X: "President Trump has taken decisive action to ensure Americans pay less for prescription drugs they need. This month, he signed my PBM Act into law to stop pharmacy benefit managers from ripping off seniors."

Rep. Gary Palmer (R-AL-6) framed it as part of a broader GOP healthcare push: "The Democrats' Unaffordable Care Act caused healthcare costs to skyrocket. @HouseGOP and @POTUS are prioritizing price transparency, lowering healthcare costs, and putting the American people FIRST."

The PBM reform law directly targets the three companies that dominate the market: CVS Caremark (a subsidiary of CVS Health), Express Scripts (a subsidiary of The Cigna Group), and OptumRx (a subsidiary of UnitedHealth Group). Together, these firms manage the vast majority of prescription drug transactions in the United States, negotiating rebates with manufacturers and setting reimbursement rates for pharmacies. The FTC has investigated their practices, and the new law codifies many of the transparency measures that reformers have sought for years.

The Pharmaceutical Care Management Association (PCMA), which represents PBMs, has been the industry's primary lobbying voice on these provisions. On the other side, the American Medical Association has advocated for PBM reform, and the National Community Pharmacists Association has long argued that PBM practices squeeze independent pharmacies.

Sen. Roger Marshall (R-KS) connected the dots between PBM reform and broader transparency efforts: "Price Transparency will cut healthcare costs for every American. Let's make it law!"

On the lobbying side, Rite Aid Corp. has been a consistent presence in drug pricing lobbying disclosures, reporting $50,000 in Fourth Quarter 2024 expenditures related to pharmacy benefit manager practices and healthcare policy. While that figure is modest compared to the industry's overall spending, it reflects the breadth of stakeholders engaged on PBM-related drug pricing legislation — from retail pharmacies to insurers to patient groups.

The question now is implementation. The 100 percent rebate pass-through requirement is a structural change to how drug money moves, and whether it translates into lower costs at the pharmacy counter will depend on how plans, PBMs, and manufacturers adjust their contracting.

Domestic Drug Manufacturing: National Security Meets Drug Pricing

The third thread gaining momentum this week is the push to strengthen domestic pharmaceutical manufacturing — a conversation that members are framing through both a national security lens and a prescription drug cost lens.

Rep. Gus Bilirakis (R-FL-12), co-chair of the Domestic Pharmaceutical Manufacturing Caucus, stated: "As co-chair of the Domestic Pharmaceutical Manufacturing Caucus, I understand that ensuring a resilient, secure supply of essential medicines is not only a public health imperative, but a critical national security priority."

Rep. Ann Wagner (R-MO-2) echoed the theme after meetings with industry stakeholders: "It's critical we bring supply chains back home to America and strengthen domestic production of crucial medicines, and it was great hearing about their ongoing efforts to achieve those goals."

This thread connects to drug pricing in important ways. A significant portion of generic drugs and active pharmaceutical ingredients are manufactured overseas, particularly in China and India. Supply chain disruptions can lead to drug shortages, which in turn can drive up prescription drug costs. Members pushing for domestic manufacturing argue that reshoring production would both enhance security and stabilize pricing.

The generic drug and biosimilar industry is directly affected. Companies like Viatris, which reported approximately $640,000 in Third Quarter 2025 lobbying expenditures on generic drug issues including formulary design, and Teva Pharmaceutical, the world's largest generic drug manufacturer, have a direct stake in how domestic manufacturing incentives are structured. The Association for Accessible Medicines (AAM), which represents generic and biosimilar manufacturers, has been active in these policy discussions.

No specific legislation on domestic pharmaceutical manufacturing was introduced this week, and no hearings are scheduled. But the volume of member communications on the topic suggests it is being positioned as a priority — potentially as a component of broader reconciliation or trade legislation moving through Congress.

The intersection with tariff policy adds another dimension. As the administration pursues trade actions that could affect pharmaceutical imports, the domestic manufacturing push provides a policy rationale that bridges traditional Republican trade hawkishness with the drug pricing concerns that animate both parties.

With 298 bills introduced, 186 organizations actively lobbying, and over 2,500 congressional communications logged on drug pricing, this remains one of the most contested policy areas in Washington. The coming weeks will test whether any of these three threads — MFN codification, PBM reform implementation, or supply chain reshoring — can translate congressional energy into concrete action.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article